Skip to main content
. Author manuscript; available in PMC: 2020 Jul 22.
Published in final edited form as: J Hypertens. 2018 Jun;36(6):1326–1341. doi: 10.1097/HJH.0000000000001708

FIGURE 3.

FIGURE 3

Kidney (a) and left ventricle (LV) myocardial (d) CYP2C23, kidney soluble epoxide hydrolase (sEH) and LV myocardial (b and e) and kidney and LV myocardial (c and f) CYP4A protein expression in Hannover Sprague–Dawley (HanSD, transgene-negative) rats and in heterozygous Ren-2 transgenic rats (TGR), and effects of soluble epoxide hydrolase inhibitor (sEHi) or epoxyeicosatrienoic acid analogue (EET-A) given alone or combined sEHi and EET-A treatment.*P<0.05 versus unmarked values.